Overall, 31% of ovarian cancer patients and 36% of control women carried one of the two common founder mutations of BRCA1 (185 del AG or 5382 ins C) or the single common founder mutation of BRCA2 (6174 del T). This evidence concerns the gene BRCA1 and ovarian carcinoma.